Abstract:Ethnopharmacological relevance Moluodan concentrated pill (MLD) is a traditional herbal formula used in China for the treatment of chronic atrophic gastritis (CAG). However, its pharmacological mechanism of action remains unclear. Aim of the study The aim of this study was to investigate the therapeutic effect and mechanism of action of MLD in the treatment of CAG using network pharmacology and in vivo experiments. Materials and methods The active compounds of MLD were determined using network pharmacology, utilizing various Chinese medicine databases such as the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, Traditional Chinese Medicine Integrated Database, Integrative Pharmacology-based Research Platform of Traditional Chinese Medicine, and a comprehensive database of Traditional Chinese Medicine on Immuno-Oncology. The compounds found in the root of Anemone altaica Fisch. were extracted from the China National Knowledge Infrastructure literature database. Additionally, the Swiss Target Prediction database and Similarity Ensemble Approach were employed to identify the potential targets of these components. CAG-related targets were gathered from the GeneCards and DisGeNET databases. Protein-protein interactions (PPIs) of the genes associated with the drug-disease crossover were examined, and a core PPI network was constructed using the STRING database (version 11.5) and Cytoscape (version 3.7.2). A gene-pathway network was established to identify significant target genes and pathways through Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Finally, based on these findings and existing data, the tumor necrosis factor (TNF) signaling pathway was selected for further validation through in vivo experiments. Results A total of 724 active molecules in MLD yielded 961 identified target genes, of which 179 were found to be potentially associated with CAG. From the common targets, a PPI network revealed ten core targets. Enrichment analysis suggested that MLD may primarily target TNF and AKT in the treatment of CAG. Essential signaling pathways, such as the PI3K-AKT and TNF pathways, were found to be crucial for the therapeutic effects of MLD on CAG. Furthermore, potential interactions and crosstalk between these pathways were identified. Moreover, we confirmed that MLD effectively improved gastric mucosa atrophy and cellular ultrastructural damage, while increasing pepsinogen secretion and decreasing gastrin , somatostatin, and motilin levels. Subsequent molecular biology studies in rat models of CAG demonstrated that MLD treatment significantly reduced the expression levels of TNF-α, phosphatidylinositol 3′-kinase (PI3K), and phosphorylated Akt ( P < 0.05). Notably, the expression of nuclear factor kappa-B (NF-κB) exhibited a contrasting trend ( P < 0.05), potentially associated with the crucial tumor suppressor role of NF-κB p105. Conclusion This study provides evidence that MLD effectively alleviates stomach mucosal atrophy through modulation of the TNF/PI3K/AKT signaling pathway. These findings establish a solid theoretical foundation for the practical management of CAG.

Randomized Double-Blind Clinical Trial of Moluodan () for the Treatment of Chronic Atrophic Gastritis with Dysplasia.

Effectiveness and safety of Moluodan in the treatment of precancerous lesions of gastric cancer: A randomized clinical trial

Clinical Efficacy of Moluodan in the Treatment of Chronic Atrophic Gastritis: A Protocol for Systematic Review and Meta-Analysis

Pharmacodynamics and pharmacological mechanism of Moluodan concentrated pill in the treatment of atrophic gastritis: A network pharmacological study and in vivo experiments

Diagnosis and Treatment Strategy for Gastric Mucosal Dysplasia

A Randomized Double-blind Clinical Trial of Weierkang Pills for the Treatment of Chronic Atrophic Gastritis.

Network pharmacology to unveil the mechanism of Moluodan in the treatment of chronic atrophic gastritis

Treatment of Chronic Atrophy Gastritis of Rats with Montmorillonites from Different Sources

Moluodan Promotes DSS-induced Intestinal Inflammation Involving the Reprogram of Macrophage Function and Polarization.

A Randomized Controlled Multicenter Trial of Rebamipide on Chronic Non-Atrophic Gastritis

Efficacy and Safety of Elian Granules in Treating Chronic Atrophic Gastritis: Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

Studies of the Pathologic Change of Gastric Mucosa and Regulating Factors of Cell Proliferation in Rats with Experimental Chronic Atrophic Gastritis

Effects of Helicobacter pylori and Moluodan on the Wnt/β-catenin signaling pathway in mice with precancerous gastric cancer lesions

Efficacy of tepronone and folic acid in the treatment of chronic atrophic gastritis evaluated by the marking targeting biopsy

Morphological and Pathologic Changes of Experimental Chronic Atrophic Gastritis (CAG) and the Regulating Mechanism of Protein Expression in Rats

Effects of Moxibustion on Cell Proliferative Factors in Gastric Mucosa in Rats with Precancerous Lesions of Chronic Atrophic Gastritis

Randomised Clinical Trial Investigating the Effects of Combined Administration of Octreotide and Methylglucamine Diatrizoate in the Older Persons with Adhesive Small Bowel Obstruction

The mechanism of folic acid on N-methyl-N’-nitro-N-nitrosoguanidine-induced chronic atrophic gastritis through the PI3K/Akt pathway.

BanxiaxiexinTangTreatment of Chronic Atrophic Gastritis Multicenter Randomized Parallel-group Study

Efficacy of mosapride therapy on gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled cross-over study

Modified Xiaochaihu Decoction for gastroesophageal reflux disease: A randomized double-simulation controlled trial